Cancer Clinical Trials in Novara

21 recruitingNovara, Italy

Showing 120 of 21 trials

Recruiting
Phase 3

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation390 enrolled34 locationsNCT06931717
Recruiting
Phase 3

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled281 locationsNCT06393374
Recruiting
Phase 3

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Advanced Breast Cancer
MedSIR240 enrolled69 locationsNCT06382948
Recruiting
Phase 3

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC868 enrolled226 locationsNCT06077760
Recruiting
Phase 3

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 3

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 2

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Advanced Breast CancerAdvanced Breast Carcinoma
MedSIR200 enrolled47 locationsNCT06486883
Recruiting
Phase 2

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer
Bristol-Myers Squibb76 enrolled50 locationsNCT06946797
Recruiting
Phase 2Phase 3

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled189 locationsNCT04534205
Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 3

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting

Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

Metastatic Breast Cancer
European Institute of Oncology1,000 enrolled37 locationsNCT06994377
Recruiting
Phase 3

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Phase 2

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

HER2-positive Breast Cancer
MedSIR165 enrolled36 locationsNCT06172127
Recruiting

EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS1,000 enrolled29 locationsNCT06894173
Recruiting

Artificial Intelligence-based Platform, Integrating Pathologic, Imaging and Molecular Profiles of Prostate Cancer

Prostate Cancer
Azienda Ospedaliero Universitaria Maggiore della Carita400 enrolled1 locationNCT06468332
Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Breast AdenocarcinomaBreast Cancer Stage IV
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano3,500 enrolled24 locationsNCT06805812
Recruiting

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Non-small Cell Lung CancerNSCLCNSCLC, Stage I+1 more
MSD Italia S.r.l.600 enrolled25 locationsNCT06467383
Recruiting

DOsimetry and Radiation Induced NAusea in Head and Neck Cancers

Head and Neck Cancer
European Institute of Oncology180 enrolled14 locationsNCT06341985